AP
VRDN icon

Antipodes Partners’s Viridian Therapeutics VRDN Stock Holding History

Antipodes Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-834
Closed -$16.3K – 155
2026
Q1 		$16.3K Sell
834
-316
-27% -$9.38K ﹤0.01% 121
2025
Q4 		$35.8K Buy
+1,150
New +$31.5K ﹤0.01% 114

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Antipodes Partners's VRDN Position: Q2 2026 in Review

Antipodes Partners sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 834 shares — an estimated $16.3K sold.

Antipodes Partners first reported a position in VRDN in Q4 2025 and held it in 2 quarters. The position peaked at $35.8K in Q4 2025. 71 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Antipodes Partners reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 834 Viridian Therapeutics shares in Q2 2026, an estimated $16.3K.
  • Antipodes Partners first reported a position in Viridian Therapeutics in Q4 2025 and held it in 2 quarters.
  • Antipodes Partners's Viridian Therapeutics position peaked at $35.8K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.